PharmaEssentia Corporation in Taiwan reported a ransomware incident attributed to thegentlemen, impacting its operations and systems. #Taiwan
Incident Details
- Victim: PharmaEssentia Corporation
- Sector: Healthcare
- Country: TW
- Actor: thegentlemen
- Source:
- Discovered: 2026-09-09T22:09:03.354275+00:00
- Published: 2026-09-09T15:03:59+00:00
Information
- Taiwanese global biopharma founded in 2003, recognized for Besremi (ropeginterferon alfa-2b), the first drug developed in Taiwan ever approved by the FDA.
- Besremi is the only polycythemia vera therapy approved in both the US and EU, with disease-modifying potential and home dosing every two weeks.
- The treatment reduces JAK2V617F mutant allele frequency, positioning it as a premium rare-disease asset compared with hydroxyurea and Jakafi.
- The company reported over $197M in revenue in 2024 with an approximate 89% gross margin.
- Listed on TPEX under 6446, the stock has risen about 5x since 2024.
- Future growth focuses on essential thrombocythemia Phase 3 development and myelofibrosis.
- It stands out as a local biotech success story that moved a molecule from out-licensing to FDA approval and global commercialization.
Disclaimer: This post is based on public claims made by the ransomware group "thegentlemen". I cannot confirm the accuracy of the information. However, I would be happy to share any official statement from the affected organization to provide clarification.